Michael Johnson of Johnson Becker in Minneapolis has been named lead counsel for coordinating depositions for plaintiffs alleging that they developed pancreatic cancer as a result of taking one of four incretin-based drugs.
On the defense side, Richard Goetz of O’Melveny & Myers was named lead counsel for coordinating depositions for Amylin Pharmaceuticals LLC; Nina Gussack of Pepper Hamilton lead counsel for Eli Lily & Co.; Doug Marvin of Williams & Connolly for Merck Sharp & Dohme Corp.; and Loren Brown of DLA Piper for Novo Nordisk Inc.
